- Home
- CLDI vs IMNN Comparison
CLDI vs IMNN Comparison
Compare CLDI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- IMNN
- Stock Information
- Founded
- CLDI 2014
- IMNN 1982
- Country
- CLDI United States
- IMNN United States
- Employees
- CLDI N/A
- IMNN N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- IMNN Health Care
- Exchange
- CLDI Nasdaq
- IMNN Nasdaq
- Market Cap
- CLDI 10.2M
- IMNN 12.1M
- IPO Year
- CLDI N/A
- IMNN 1985
- Fundamental
- Price
- CLDI $0.23
- IMNN $0.77
- Analyst Decision
- CLDI Strong Buy
- IMNN Buy
- Analyst Count
- CLDI 1
- IMNN 2
- Target Price
- CLDI $10.00
- IMNN $14.00
- AVG Volume (30 Days)
- CLDI 1.8M
- IMNN 5.4M
- Earning Date
- CLDI 08-12-2025
- IMNN 08-13-2025
- Dividend Yield
- CLDI N/A
- IMNN N/A
- EPS Growth
- CLDI N/A
- IMNN N/A
- EPS
- CLDI N/A
- IMNN N/A
- Revenue
- CLDI N/A
- IMNN N/A
- Revenue This Year
- CLDI N/A
- IMNN N/A
- Revenue Next Year
- CLDI N/A
- IMNN N/A
- P/E Ratio
- CLDI N/A
- IMNN N/A
- Revenue Growth
- CLDI N/A
- IMNN N/A
- 52 Week Low
- CLDI $0.20
- IMNN $0.37
- 52 Week High
- CLDI $3.89
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- CLDI 21.13
- IMNN 40.14
- Support Level
- CLDI $0.31
- IMNN $0.93
- Resistance Level
- CLDI $0.33
- IMNN $1.03
- Average True Range (ATR)
- CLDI 0.04
- IMNN 0.18
- MACD
- CLDI -0.01
- IMNN -0.10
- Stochastic Oscillator
- CLDI 14.83
- IMNN 1.39
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).